

RECEIPT OF \$4.5M COLLABORATION FEE

PERTH, Australia and SAN FRANCISCO, California – 16 February 2024

PYC Therapeutics Limited (ASX:PYC) announced today the receipt of the \$4.5 million up front fee from the AI-Driven drug discovery collaboration previously announced 2 January 2024. PYC has also completed remaining contractual requirements for this collaboration. PYC will contribute a total of \$10.1 million to the project in three instalments (\$6.5 million in January 2024 and two payments of \$1.8 million in June 2024 and October 2024).

Please refer to ASX announcement 2 January 2024 for further information on the collaboration agreement.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials and is now progressing multiple 'fast-follower' programs into the clinic. For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited

CONTACTS:

INVESTORS and MEDIA
info@pyctx.com

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.20222232>